Cited by 1,171BRCA gene mutations in cancerWomen's cancer prevention and managementBreast Lesions and Carcinomas

Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

Rebbeck, Timothy R., Friebel, Tara, Lynch, Henry T., Neuhausen, Susan L., van ’t Veer, Laura, Garber, Judy E., Evans, Gareth R., Narod, Steven A. +5 more·2004·Journal of Clinical Oncology

Abstract

Purpose Data on the efficacy of bilateral prophylactic mastectomy for breast cancer risk reduction in women with BRCA1 and BRCA2 (BRCA1/2) mutations are limited, despite the clinical use of this risk-management strategy. Thus, we estimated the degree of breast cancer risk reduction after surgery in women who carry these mutations. Patients and methods Four hundred eighty-three women with disease-associated germline BRCA1/2 mutations were studied for the occurrence of breast cancer. Cases were mutation carriers who underwent bilateral prophylactic mastectomy and who were followed prospectively from the time of their center ascertainment and their surgery, with analyses performed for both follow-up periods. Controls were BRCA1/2 mutation carriers with no history of bilateral prophylactic mastectomy matched to cases on gene, center, and year of birth. Both cases and controls were excluded for previous or concurrent diagnosis of breast cancer. Analyses were adjusted for duration of endogenous ovarian hormone exposure, including age at bilateral prophylactic oophorectomy if applicable. Results Breast cancer was diagnosed in two (1.9%) of 105 women who had bilateral prophylactic mastectomy and in 184 (48.7%) of 378 matched controls who did not have the procedure, with a mean follow-up of 6.4 years. Bilateral prophylactic mastectomy reduced the risk of breast cancer by approximately 95% in women with prior or concurrent bilateral prophylactic oophorectomy and by approximately 90% in…

Integrity signals

Registry

Crossref · 10.1200/jco.2004.04.188

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Rebbeck, T. R., Friebel, T., Lynch, H. T., Neuhausen, S. L., van ’t Veer, L., Garber, J. E., Evans, G. R., Narod, S. A., Isaacs, C., Matloff, E., Daly, M. B., Olopade, O. I., & Weber, B. L.
Affiliations
  • Creighton University (US)
  • From the PROSE Study Group; the Center for Clinical Epidemiology and Biostatistics, Abramson Family Cancer Research Institute, The University of Pennsylvania; and Fox Chase Cancer Center, Philadelphia, PA; Creighton University, Omaha, NE; Division of Genetic Epidemiology, Department of Medicine, University of California Irvine, Irvine, CA; Women’s College Hospital, Toronto, Ontario, Canada; the Netherlands Cancer Institute, Amsterdam, the Netherlands; Dana-Farber Cancer Institute, Boston, MA; St. Mary’s...
Venue
Journal of Clinical Oncology
Published
2004-03-15
Volume
22
Issue
6
Pages
1055-1062
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2147058464
Cited by
1,171
References
2
Citations by year
2026: 25 · 2025: 25 · 2024: 45 · 2023: 43 · 2022: 55 · 2021: 48 · 2020: 36 · 2019: 51 · 2018: 57 · 2017: 59 · 2016: 67 · 2015: 52 · 2014: 62 · 2013: 53 · 2012: 51
FWCI
32.13
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • TSpace (University of Toronto) (submittedVersion)
Funders
  • National Institutes of Health (5r01ca057601-07)
  • National Cancer Institute (R01-CA83855, CA-57601, R01CA083855, CA74415, N01 CN6700, R01CA074415)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
Keywords
bilateral prophylactic mastectomy, breast cancer risk reduction, BRCA1 mutation, BRCA2 mutation, germline mutation carriers, prophylactic oophorectomy, breast cancer prevention
MeSH terms
Adult, Breast Neoplasms, Europe, Female, Heterozygote, Humans, Mastectomy, Middle Aged, Mutation, North America, Prospective Studies, Retrospective Studies, Proportional Hazards Models, Case-Control Studies, Treatment Outcome, Risk Assessment, Genes, BRCA1, Genetic Predisposition to Disease, Genes, BRCA2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review